Oncotarget

Research Papers:

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

Jing Wang, Min Zhou, Qi-Guo Zhang, Jingyan Xu, Tong Lin, Rong-Fu Zhou, Juan Li, Yong-Gong Yang, Bing Chen and Jian Ouyang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9708-9716. https://doi.org/10.18632/oncotarget.14182

Metrics: PDF 1391 views  |   HTML 1553 views  |   ?  


Abstract

Jing Wang1,*, Min Zhou1,*, Qi-Guo Zhang1,*, Jingyan Xu1,*, Tong Lin1, Rong-Fu Zhou1, Juan Li1, Yong-Gong Yang1, Bing Chen1, Jian Ouyang1

1Department of Hematology, The Affiliated DrumTower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, PR China

*These authors contributed equally to this work and should be considered as co-first authors

Correspondence to:

Jian Ouyang, email: ouyang211@hotmail.com

Bing Chen, email: chenbing2004@126.com

Keywords: diffuse large B-cell lymphoma, p65, NF-κB, international prognostic index

Received: July 25, 2016    Accepted: November 22, 2016    Published: December 26, 2016

ABSTRACT

Purpose: We estimated the expression of nuclear factor kappa B/p65 in non-germinal center B-cell-like subtype diffuse large B-cell lymphoma, to investigate its relationship to clinicopathological features, and to further evaluate its prognostic value and clarify its impact on survival.

Results: Among the 49 patients enrolled in this study, 14 (28.6%) had positive p65 expression. The negative p65 group had significantly better survival compared to the positive p65 group in terms of both the 3-year estimated OS (91.2% vs. 39.3%, p = 0.003) and PFS (75.6% vs. 26.5%, p = 0.002). In patients with 4 or more risk factors, p65 was an independent prognostic factor of OS (HR 5.99, 95%CI=1.39-25.75, p=0.016) and PFS (HR 4.01, 95%CI=1.15-14.00, p=0.029).

Materials and Methods: The expression of the NF-κB/p65 protein was deteremined by immunohistochemistry in 49 non-GCB DLBCL. Survival was assessed by the Kaplan–Meier method and Cox multivariate analysis. The median patient follow-up period was 24 months.

Conclusions: The expression of NF-κB/p65 has prognostic value in high risk non-GCB DLBCL, and it is a suitable target for the development of new therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14182